SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:14971500.
  • 2
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:21292139.
  • 3
    Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:1330613311.
  • 4
    van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18:99103.
  • 5
    Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:24422449.
  • 6
    Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:39083914.
  • 7
    Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947957.
  • 8
    Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:23802388.
  • 9
    Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735742.
  • 10
    Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239246.
  • 11
    Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [serial online]. PloS Med. 2005;2:e73.
  • 12
    Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:10391043.
  • 13
    Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786792.
  • 14
    Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [serial online]. Sci Transl Med. 2011;23:3:75ra26.
  • 15
    Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17:11691180.
  • 16
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205216.
  • 17
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228247.
  • 18
    Nishino M, Jagannathan JP, Ramaiya N, et al. Pictorial review of the new Response Evaluation Criteria in Solid Tumors: revised RECIST guideline version 1.1—What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281229.
  • 19
    Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:74127420.
  • 20
    Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012;198:737745.
  • 21
    Nishino M, Jackman DM, Hatabu H, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011;18:424436.
  • 22
    Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:17531759.
  • 23
    Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13:51505155.
  • 24
    Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357360.
  • 25
    Nishino M, Cardarella S, Dahlberg SE, et al. Radiographic response assessment and therapeutic treatment decisions at the time of RECIST progression in EGFR-mutant NSCLC. Lung Cancer. 2013;79:283288.
  • 26
    Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012;7:17221727.
  • 27
    Zhao B, Schwartz LH, Moskowitz CS, et al. Lung cancer: computerized quantification of tumor response—initial results. Radiology. 2006;241:892898.
  • 28
    Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009;252:263272.
  • 29
    Mozley PD, Schwartz LH, Bendtsen C, et al. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010;21:17511755.
  • 30
    Mozley PD, Bendtsen C, Zhao B, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5:1925.
  • 31
    Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of emerging clinical tool. Acad Radiol. 2011;18:5462.
  • 32
    Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:10391044.
  • 33
    Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:13811387.
  • 34
    Kozak MM, Murphy JD, Schipper ML, et al. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011;6:920906.
  • 35
    Nishino M, Dahlberg SE, Cardarella S, et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI [published online ahead of print June 19, 2013]. J Thorac Oncol. 2013.
  • 36
    Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Phil Trans R Soc (Lond). 1825;115:513.
  • 37
    Castro MA, Klamt F, Grieneisen VA, Grivicich I, Moreira JC. Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines. Cell Prolif. 2003;36:6573.
  • 38
    Demicheli R, Foroni R, Ingrosso A, Pratesi G, Soranzo C, Tortoreto M. An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res. 1989;49:65436546.
  • 39
    Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst. 1977;58:17351741.
  • 40
    Looney WB, Trefil JS, Schaffner JC, Kovacs CJ, Hopkins HA. Solid tumor models for the assessment of different treatment modalities. I. Radiation-induced changes in growth rate characteristics of a solid tumor model. Proc Natl Acad Sci U S A. 1975;72:26622666.
  • 41
    Looney WB, Trefil JS, Schaffner JG, Kovacs CJ, Hopkins HA. Solid tumor models for the assessment of different treatment modalities: systematics of response to radiotherapy and chemotherapy. Proc Natl Acad Sci U S A. 1976;73:818822.
  • 42
    Looney WB, Trefil JS, Hopkins HA, Kovacs CJ, Ritenour R, Schaffner JG. Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy. Proc Natl Acad Sci U S A. 1977;74:19831987.
  • 43
    Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:58735882.
  • 44
    Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:44064414.
  • 45
    Jackman DM, Cioffredi LA, Lindeman N, et al. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma [abstract]. J Clin Oncol. 2009;27:15(suppl). Abstract 8065.
  • 46
    Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760766.
  • 47
    Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer. 2004;44:221230.
  • 48
    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963974.
  • 49
    Levy A, Hollebecque A, Ferte C, et al. Tumor assessment criteria in phase I trials: beyond RECIST [letter]. J Clin Oncol. 2013;31:395.
  • 50
    Gomez-Roca C, Koscielny S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011;47:25122516.
  • 51
    Stein WD, Wilkerson J, Kim ST, et al. Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res. 2012;18:23742381.
  • 52
    Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in 5 intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17:907917.
  • 53
    Park K, Tsai CM, Ahn M, et al. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012;30(suppl). Abstract TPS7614.